Shared insight on the respective roles of PSMA-PET imaging and PSA doubling time in the current prostate cancer treatment paradigm.
Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center
Advertisement
Articles by Evan Y. Yu, MD, Fred Hutchinson Cancer Research Center
Broad discussion on the evolution of care in prostate cancer from both the therapeutic and imaging standpoints.
Advertisement
Latest Updated Articles
Overview of Improvements in Prostate Cancer ManagementMarch 30th 2022
Advertisement
Advertisement
Trending on OncLive
1
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
2
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
3
Tuspetinib Plus Venetoclax and Azacitidine Is Safe and Effective Across Molecular Subgroups in Newly Diagnosed AML
4
Dr Voorhees on Efficacy Data for Talquetamab-Based Combos in R/R Myeloma From MonumenTAL-3
5